编辑文章 - 后台系统

编辑文章

编辑文章

文章标题：

关键字：

所属疾病：

所属类别：

标　　签：

文章主图*

点击“Select image”更换图片

Select image Change Remove

注意! 最佳图片尺寸800*800

内容详情：

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"><span style="font-size:10.5pt"><span style="font-family:Calibri"><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#333333"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">携带不同基因结构的乳腺癌患者易产生磷脂酰肌醇</font><font face="微软雅黑">-3-激酶催化σ亚基(PIK3CA)的基因突变,HR+/HER2-乳腺癌患者发生PIK3CA基因突变率约40％</font></span></span></span></span></span></span></span><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#333333"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">。</font></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"> </p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"><span style="font-size:10.5pt"><span style="font-family:Calibri"><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><a href="http://www.india-drugstore.com/p/story_detail.php?id=1923&art_cate_value=0&art_navid_value=2"><span style="color:#3498db;"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><strong><font face="微软雅黑"><span style="background-color:#f1c40f;">阿培利司</span></font></strong></span></span></span></span></a><span style="color:#222222"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">+内分泌治疗（氟维司群或来曲唑）用于既往治疗（包括CDKi）进展的PIK3CA突变HR+/HER2-晚期乳腺癌的首个研究</font></span></span></span></span></span></span></span><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#222222"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">。</font></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"> </p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"><span style="font-size:10.5pt"><span style="font-family:Calibri"><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#333333"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">阿培利西</font><font face="微软雅黑">(Alpelisib)作为磷脂酰肌醇-3-激酶(PI3K)抑制剂,用于治疗激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性、PIK3CA基因突变的绝经后女性及男性晚期或转移性乳腺癌患者,常见的不良反应包括高血糖、腹泻、皮疹及肺炎等</font></span></span></span></span></span></span></span><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#333333"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">。</font></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"> </p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"><span style="font-size:10.5pt"><span style="font-family:Calibri"><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#222222"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">三阴性乳腺癌（</font>TNBC）占所有乳腺癌的20%，预后相对较差，其有效的治疗药物及治疗方案仍在探索。</span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"><span style="font-size:10.5pt"><span style="font-family:Calibri"><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#222222"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal">Alpelisib是一款口服小分子α特异性PI3K抑制剂，其有效成分可以特异性抑制PI3K/AKT激酶（或蛋白激酶B）信号传导途径中的PIK3，从而抑制PI3K信号传导途径的激活。奥拉帕利为PARP抑制剂，可以通过抑制肿瘤细胞DNA损伤修复，导致BRCA突变肿瘤细胞死亡。</span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"><span style="font-size:10.5pt"><span style="font-family:Calibri"><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#222222"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><img alt="" src="../upload/646b38cb3cb29362042368.jpg" style="width: 800px; height: 632px;" /></span></span></span></span></span></span></span></span></span></p>

首页显示：

显示不显示

热门文章：

是否

阅读：